(Q36740473)

16 August 2017

1 reference

title

Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis (English)

1 reference

16 August 2017

1 reference

1

Nicola Bizzaro

1 reference

16 August 2017

publication date

1 January 2007

1 reference

Clinical Chemistry and Laboratory Medicine

16 August 2017

published in

1 reference

16 August 2017

volume

45

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

150-157

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Anti-keratin antibodies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Citrullination: a small change for a protein with great consequences for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Defects in the regulation of B cell apoptosis are required for the production of citrullinated peptide autoantibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Citrullination of synovial proteins in murine models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Insights into rheumatoid arthritis derived from the Sa immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Vimentin is secreted by activated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Clinical utility of the anti-CCP assay in patients with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Clinical utility of the anti-CCP assay: experiences with 700 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Mixed cryoglobulinaemia and chronic hepatitis C virus infection: the rheumatic manifestations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Hepatitis C virus and arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Diagnostic performance and predictive value of anti-citrullinated peptide antibodies for diagnosis of rheumatoid arthritis: toward more accurate detection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.027

21 January 2018

Identifiers

DOI

10.1515/CCLM.2007.027

1 reference

16 August 2017

1 reference